Nyrada Inc – Nyrada Half Year FY2024 Results
Highlights: •Brain Injury Program: -Stroke model study underway with drug well tolerated to date. Efficacy results imminent. -Walter Reed brain… Read more
Nyrada Inc Half – year Report
Nyrada Inc. Appendix 4D Half-year report
Nyrada Inc – Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Brain Injury Program: -Stroke model study underway with drug well tolerated to date, efficacy results imminent. -Walter Reed brain… Read more
Nyrada Receives A$3.54M R&D Tax Incentive Rebate
Nyrada Inc (ASX: NYR), a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases… Read more
Nyrada – AGM Presentation
James Bonnar CEO – Presentation to the Annual General Meeting
Nyrada AGM 2023 Chair’s Address
“I would like to take this opportunity to reflect on our Company and progress in the prior financial year. 2023… Read more
Nyrada – 2023 AGM Chair Letter to Shareholders
On Monday 20 November 2023, the Company will be holding its 2023 Annual General Meeting (AGM).
Nyrada Quarterly Activities Report & Appendix 4C
Highlights: •Cholesterol-Lowering Program: -New PCSK9 inhibitor candidate identified and progressing to assessment. -Alternative applications for NYX-1492 investigated. -Peer-reviewed journal paper… Read more
Nyrada Inc Annual Report
Please follow the link below to see the Annual Report for FY23.
